Leading provider of health care technology, Cerner Corporation CERN announced that it recently entered into an agreement to provide San Juan Regional Medical Center with a new electronic health record (EHR) platform. San Juan Regional Medical Center is a non-profit, acute care hospital and Level III Trauma Center with 194 licensed beds.
Cerner’s share price movement in the past three months was unsatisfactory. The company registered a gain of only 5.79%, lower than the Zacks categorized Medical info-systems sub-industry’s gain of 6.94%. Over the last one year, Cerner has lost 6.19%.
Furthermore, the estimate revision trend for the current fiscal year remains unfavorable with two estimates moving downward over the last three months. The company’s current fiscal year estimate slipped by 3 cents over the past three months, pointing to looming concerns ahead.
Per the agreement, San Juan Regional Medical Center will implement Cerner’s flagship HealtheIntent, a real-time population health management platform designed to aggregate data from multiple sources. San Juan Regional Medical Center’s clinicians will use HealtheEDW, Cerner’s proprietary enterprise data warehouse solution, to gain insights and analyze data to improve care coordination.
In recent times, the Population Health service businesses drove solid growth for Cerner. In the recently reported fourth-quarter 2016 results, it witnessed solid growth owing to high demand for HealtheIntent solutions. Also, the company’s booked new orders were worth $1.44 billion, up 7% on a year-over-year basis.
Cerner designs, develops, markets, installs and supports information technology and content solutions for healthcare organizations and consumers. The company's integrated suite of solutions enable healthcare providers to improve operating effectiveness, reduce costs and improve the quality of care as measured by clinical outcomes.
Zacks Rank & Key Picks
Currently, Cerner has a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector include Cymabay Therapeutics, Inc. CBAY, Dicerna Pharmaceuticals, Inc. DRNA, and Dimension Therapeutics, Inc. DMTX. Each of the three stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cymabay Therapeutics has a long-term expected earnings growth rate of approximately 15%. Notably, the stock posted an impressive one-year return of 49.4%.
Dicerna Pharmaceuticals posted a positive earnings surprise of 100% in the last reported quarter. Additionally, the company has a promising one-year return of almost 75.8%.
Dimension Therapeutics has a long-term expected earnings growth rate of approximately 20%. Notably, the stock registered an impressive one-year return of roughly 19.5%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cerner Corporation (CERN): Free Stock Analysis Report
Dicerna Pharmaceuticals, Inc. (DRNA): Free Stock Analysis Report
CymaBay Therapeutics Inc. (CBAY): Free Stock Analysis Report
Dimension Therapeutics, Inc. (DMTX): Free Stock Analysis Report
To read this article on Zacks.com click here.